Impact of pretransplant rifaximin therapy on early post–liver transplant infections
Jamak Modaresi Esfeh, Ibrahim A. Hanouneh, Christine E. Koval, Christopher Kovacs, Deepan S. Dalal, Kianoush Ansari‐Gilani, Bradley D. Confer, Bijan Eghtesad, Nizar N. Zein, K. V. Narayanan Menon – 3 February 2014 – Bacterial and fungal infections are major causes of morbidity and mortality after liver transplantation (LT). The role of intestinal decontamination in the prevention of post‐LT infections is controversial. Rifaximin is widely used for the treatment of hepatic encephalopathy. The effect of rifaximin on post‐LT infections is unknown.